Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 12;14(4):e0214970.
doi: 10.1371/journal.pone.0214970. eCollection 2019.

Stereotactic body radiation therapy for locally advanced pancreatic cancer

Affiliations

Stereotactic body radiation therapy for locally advanced pancreatic cancer

Jinhong Jung et al. PLoS One. .

Abstract

Purpose: Stereotactic body radiation therapy (SBRT) is a promising treatment modality for locally advanced pancreatic cancer (LAPC). We evaluated the clinical outcomes of SBRT in patients with LAPC.

Patients and methods: We retrospectively analyzed the medical records of patients with LAPC who underwent SBRT at our institution between April 2011 and July 2016. Fiducial markers were implanted using endoscopic ultrasound guidance one week prior to 4-dimensional computed tomography (CT) simulation and daily cone beam CT was used for image guidance. Patients received volumetric modulated arc therapy or intensity modulated radiotherapy using respiratory gating technique. A median dose of 28 Gy (range, 24-36 Gy) was given over four consecutive fractions delivered within one week. Survival outcomes including freedom from local disease progression (FFLP), progression-free survival (PFS), and overall survival (OS) were analyzed. Acute and late toxicities related to SBRT were assessed.

Results: A total of 95 patients with LAPC were analyzed, 52 of which (54.7%) had pancreatic head cancers. Most (94.7%) had received gemcitabine-based chemotherapy. The 1-year FFLP rate was 80.1%. Median OS and PFS were 16.7 months and 10.2 months, respectively; the 1-year OS and PFS rates were 67.4% and 42.9%, respectively. Among 79 patients who experienced failure, the sites of first failures were isolated local progressions in 12 patients (15.2%), distant metastasis in 55 patients (69.6%), and both in 12 patients (15.2%). Seven patients (7.4%) were able to undergo surgical resection after SBRT and four had margin-negative resections. Three patients (3.2%) had grade 3 nausea/vomiting during SBRT, and late grade 3 toxicity was observed in another three patients.

Conclusions: LAPC patients who received chemotherapy and SBRT had favorable FFLP and OS with minimal treatment-related toxicity. The most common pattern of failure was distant metastasis, which warrants further studies on the optimal scheme of chemotherapy and SBRT.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Protocol for marker-guided gated volumetric-modulated arc therapy.
The protocol consists of two steps—pre-treatment and in-treatment. (a) Pre-treatment: patient alignment and image guidance are performed. If alignment is significantly out of range at each procedure, patient alignment is performed again. (b) In-treatment: after delivering the first arc dose, the half-time fiducial markers are verified.
Fig 2
Fig 2
Kaplan-Meier curves of (a) freedom from local disease progression, (b) overall survival, and (c) progression-free survival in the study population.

References

    1. Timmerman RD, Kavanagh BD, Cho LC, Papiez L, Xing L. Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol. 2007; 25: 947–952. 10.1200/JCO.2006.09.7469 - DOI - PubMed
    1. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010; 303: 1070–1076. 10.1001/jama.2010.261 - DOI - PMC - PubMed
    1. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010; 362: 1605–1617. 10.1056/NEJMra0901557 - DOI - PubMed
    1. Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, et al. Locally advanced, unresectable pancreatic cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2016; 34: 2654–2668. 10.1200/JCO.2016.67.5561 - DOI - PubMed
    1. Willett CG, Czito BG, Bendell JC, Ryan DP. Locally advanced pancreatic cancer. J Clin Oncol. 2005; 23: 4538–4544. 10.1200/JCO.2005.23.911 - DOI - PubMed

Publication types